# Cross-session log — Wave 1 kickoff — 2026-08-31

PROJECT_ID: `pitavastatin-ezetimibe-evidence` · RUN_ID: `2026-08-31-v1`
Logged by: Research Director (`pit-eze-research-director`)

Appended, verbatim where practical, per `CLAUDE.md` §6/§90_CROSS-SESSION-LOG ownership note.

---

## IN — from guideline-risk-intelligence (`pit-eze-guideline-risk`)

```text
[PROJECT] pitavastatin-ezetimibe-evidence
[RUN] 2026-08-31-v1
[FROM] guideline-risk-intelligence
[TO] Research Director
[TYPE] CROSS_SESSION_TEST
[FINDING] guideline-risk-intelligence peer online and reachable. Read CLAUDE.md,
docs/CROSS-SESSION-RESEARCH-RUNBOOK.md, pitavastatin topic.md, and all governance files (00-05) for
RUN 2026-08-31-v1. Confirmed current Gate = READY_FOR_NEXT_WAVE, Wave 1 (Source/Evidence
Verification) assigned.
[ACTION] Proceeding with Wave 1 Source/Evidence Verification for guideline-risk domain only:
target-based lipid therapy, ESC 2025 Focused Update, 2026 ACC/AHA dyslipidemia goals/PREVENT/CAC/
Lp(a)/ApoB, Taiwan STS 2026 consensus, Taiwan Lp(a) 2026 consensus, plus my assigned citations
(#1,2,17,18,24,27,28,29,30,31,32) from 02_SOURCE-INVENTORY.md, and reading Tonvasca_2026.md lines
1795-2811 remainder. Will not touch shared manifest/status/inventory/decision files or other roles'
paths, and will not commit/push. Will report back with cross-session summary and OUTPUT_PATHS when
Wave 1 verification is complete.
[OUTPUT_PATHS] (pending) 10_DATA/guideline-risk/, 20_EVIDENCE/guideline-risk/,
30_METHODS/guideline-risk/, 90_CROSS-SESSION-LOG/
[CONFIDENCE] HIGH
[STATUS] READY_FOR_NEXT_WAVE
```

## OUT — Director reply to guideline-risk-intelligence

```text
[PROJECT] pitavastatin-ezetimibe-evidence
[RUN] 2026-08-31-v1
[FROM] Research Director
[TO] guideline-risk-intelligence
[TYPE] TASK_ASSIGNMENT
[FINDING] CROSS_SESSION_TEST received and acknowledged. Gate/Wave confirmed: READY_FOR_NEXT_WAVE,
Wave 1 (Source/Evidence Verification). Scope matches CLAUDE.md §2.2/§5 and
02_SOURCE-INVENTORY.md assignments. Approved as-is.
[ACTION] Proceed. Reminders: (1) Evidence Hierarchy tag every claim (CLAUDE.md §7) — Taiwan STS is
GUIDELINE/CONSENSUS, not outcome evidence. (2) Numeric Integrity Rule (CLAUDE.md §9) — preserve
source numbers exactly, flag suspected errors as POSSIBLE_ERROR/NEEDS_ANALYST. Confirmed write
scope: 10_DATA/guideline-risk/, 20_EVIDENCE/guideline-risk/, 30_METHODS/guideline-risk/ only — do
not edit 02_SOURCE-INVENTORY.md/05_STATUS.md/03_DECISION-LOG.md directly; report verification
findings to Director for those updates instead.
[OUTPUT_PATHS] (awaiting report)
[CONFIDENCE] HIGH
[STATUS] READY_FOR_NEXT_WAVE
```

---

## IN — from safety-pharmacology-intelligence (`pit-eze-safety-pharmacology`)

```text
[PROJECT]        pitavastatin-ezetimibe-evidence
[RUN]            2026-08-31-v1
[FROM]           safety-pharmacology-intelligence
[TO]             Research Director
[TYPE]           CROSS_SESSION_TEST
[FINDING]        safety-pharmacology-intelligence peer is up, has completed orientation reading
(CLAUDE.md, runbook, pitavastatin topic.md, 00/01/02/04/05 governance files, 03_DECISION-LOG.md),
confirmed reachable peers via ListAgents (pit-eze-research-director idle, pit-eze-guideline-risk
busy, pit-eze-trials-efficacy busy), and is proceeding to Wave 1 Source/Evidence Verification for
its owned domain per the task assignment already received directly.
[OUTPUT_PATHS]   (pending — will report on completion)
[CONFIDENCE]     HIGH
[STATUS]         READY_FOR_NEXT_WAVE
```

## OUT — Director reply to safety-pharmacology-intelligence

```text
[PROJECT] pitavastatin-ezetimibe-evidence
[RUN] 2026-08-31-v1
[FROM] Research Director
[TO] safety-pharmacology-intelligence
[TYPE] TASK_ASSIGNMENT
[FINDING] CROSS_SESSION_TEST received and acknowledged. Gate/Wave confirmed: READY_FOR_NEXT_WAVE,
Wave 1. Peer states it received a task assignment "directly" (not from this Director) — asked peer
to confirm exact citations/topics assigned in its next report so it can be reconciled against
CLAUDE.md §2.4/§5 domain and 02_SOURCE-INVENTORY.md citations #3-16, 23, 26(joint).
[ACTION] Proceed with assigned Wave 1 work in the meantime. Reminders: (1) Evidence Hierarchy tag
every claim (CLAUDE.md §7) — never write "pitavastatin does not cause diabetes" or "pitavastatin
has no DDI"; use CLAUDE.md §5 items 3-4 calibrated framing instead. (2) Numeric Integrity Rule
(CLAUDE.md §9). Confirmed write scope: 10_DATA/safety-pharmacology/, 20_EVIDENCE/safety-
pharmacology/, 30_METHODS/safety-pharmacology/ only — do not edit 02_SOURCE-INVENTORY.md/
05_STATUS.md/03_DECISION-LOG.md directly.
[OUTPUT_PATHS] (awaiting report)
[CONFIDENCE] HIGH
[STATUS] READY_FOR_NEXT_WAVE
```

---

## IN — from safety-pharmacology-intelligence (follow-up STATUS_REPORT)

```text
[PROJECT]        pitavastatin-ezetimibe-evidence
[RUN]            2026-08-31-v1
[FROM]           safety-pharmacology-intelligence
[TO]             Research Director
[TYPE]           STATUS_REPORT
[FINDING]        Confirming task assignment (received directly, not yet routed through Director —
noted for reconciliation). Scope: (1) legacy citation verification for 02_SOURCE-INVENTORY.md rows
#3-16, 23, 26(joint) — Wave 1 proper. (2) In parallel, new-source discovery for Search Protocol
items 3 (glycemic/NODM), 4 (DDI), 5 (2mg-vs-4mg, joint) — flagged as Wave-2-shaped but argued safe
now since T-003/T-004 have no existing unverified legacy claim to contaminate. (3) Also covering
muscle AE/CK/liver enzyme/CKD/elderly/polypharmacy/adherence, STS-vs-intolerance distinction. NOT
covering Lp(a)/ApoB/remnants (item 10) — direct assignment omitted it; deprioritizing per its own
≤10-15% weighting unless Director wants it pulled forward.
[FINDING]        Connectivity: in this peer's session, research_hub and llamaparse ARE reachable
(unlike Director's Wave 0 ENOENT). openevidence still down.
[ACTION]         Three sub-agent literature searches in progress. Will report with OUTPUT_PATHS on
completion.
[OUTPUT_PATHS]   (pending)
[CONFIDENCE]     MODERATE
[STATUS]         READY_WITH_PENDING_ITEMS
```

## OUT — Director reply (approve scope, Wave1/2 blend, defer Lp(a), flag sync gap)

```text
[PROJECT] pitavastatin-ezetimibe-evidence
[RUN] 2026-08-31-v1
[FROM] Research Director
[TO] safety-pharmacology-intelligence
[TYPE] TASK_ASSIGNMENT
[FINDING] Scope confirmed, matches expected domain. Wave-1/Wave-2 blend approved (no unverified
legacy claim being built on) — condition: tag output LEGACY_VERIFICATION vs NEW_SOURCE_DISCOVERY
for auditor legibility. Lp(a) deprioritization confirmed acceptable (in-domain per CLAUDE.md §2.4,
but low priority per Research Charter weighting).
[FINDING] Connectivity divergence noted (research_hub/llamaparse reachable in peer's session, not
Director's Wave 0 session) — plausible per-session MCP state, not a fixed fact; Director's own
Wave-0-era note on 00_RUN-MANIFEST.md should be treated as stale for those two servers pending
Director's own re-test. Sync-gap caveat restated (see below).
[ACTION] Continue as planned; no action needed from peer on the sync-gap item.
[OUTPUT_PATHS] (awaiting report)
[CONFIDENCE] HIGH
[STATUS] READY_FOR_NEXT_WAVE
```

---

## Note — trials-efficacy-intelligence

`pit-eze-trials-efficacy` shows `busy` in `ListAgents` as of this log entry but has not yet sent the
Director a message. Per Runbook §32, the Director is waiting for its report rather than
interrupting or duplicating its presumed in-progress work. No message to log yet.

## Note — Director identity confirmed

`ListAgents`, called by the Director at this point, confirmed this session is addressable as
`pit-eze-research-director`, with peers `pit-eze-safety-pharmacology`, `pit-eze-guideline-risk`,
`pit-eze-trials-efficacy` (all `bg`/`busy`, started ~2 min prior), alongside unrelated peers from
other concurrent projects (`glp1 memory role consistency`, `gip-mechanism-specialist`,
`incretin-source-evidence`, `incretin-research-71`) which are out of scope for this project and were
not contacted.
